Cargando…
A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival – CapRI-2
BACKGROUND: The 5-year survival of patients with resected pancreatic adenocarcinoma is still unsatisfying. The ESPAC-1 and the CONKO 001 trial proofed that adjuvant chemotherapy improves 5-year survival significantly from approximately 14% to 21%. In parallel, investigators from the Virginia Mason C...
Autores principales: | Märten, Angela, Schmidt, Jan, Ose, Jennifer, Harig, Sabine, Abel, Ulrich, Münter, Marc W, Jäger, Dirk, Friess, Helmut, Mayerle, Julia, Adler, Guido, Seufferlein, Thomas, Gress, Thomas, Schmid, Roland, Büchler, Markus W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696468/ https://www.ncbi.nlm.nih.gov/pubmed/19470159 http://dx.doi.org/10.1186/1471-2407-9-160 |
Ejemplares similares
-
Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759]
por: Knaebel, HP, et al.
Publicado: (2005) -
Detectors: Calorimeters at Capri
Publicado: (1991) -
Getting heavy on Capri
Publicado: (2008) -
Détecteurs : Calorimètres à Capri
Publicado: (1991) -
Capri Symposia 1983 - 1987
por: Buccella, Franco
Publicado: (1990)